VYNE Therapeutics (VYNE) Change in Receivables (2017 - 2023)
VYNE Therapeutics (VYNE) posted Change in Receivables of $16000.0 for Q3 2023, down 87.6% on a QoQ basis from $129000.0 in Q2 2023, and down 90.42% year-over-year from $167000.0 in Q3 2022.
VYNE Therapeutics (VYNE) Change in Receivables (2017 - 2023) Analysis & Trends
VYNE Therapeutics' Change in Receivables history runs 5 years deep, the most recent figure standing at $16000.0 for Q3 2023.
- Quarterly Change in Receivables fell 90.42% year-over-year to $16000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $244000.0 (up 102.7% YoY) and the FY2018 annual result came in at -$786000.0, down 200.0% from the prior year.
- Change in Receivables was $16000.0 for Q3 2023 at VYNE Therapeutics, down from $129000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $798000.0 in Q2 2021 and bottomed at -$8.0 million in Q1 2022.
- A 3-year average of -$1.5 million and a median of -$68000.0 in 2023 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables plunged 128.95% — and 2023, when it soared 155.84%.
- VYNE Therapeutics' Change in Receivables stood at -$996000.0 in 2021, then soared by 116.77% to $167000.0 in 2022, then slumped by 90.42% to $16000.0 in 2023.
- Business Quant data shows VYNE's Change in Receivables at $16000.0 in Q3 2023, $129000.0 in Q2 2023, and -$68000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 75.30 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 16,000.00 |
| Sep 30, 2023 | 16,000.00 |
| Jun 30, 2023 | 129,000.00 |
| Jun 30, 2023 | 129,000.00 |
| Mar 31, 2023 | -68,000.00 |
| Mar 31, 2023 | -68,000.00 |
| Sep 30, 2022 | 167,000.00 |
| Sep 30, 2022 | 167,000.00 |
| Jun 30, 2022 | -231,000.00 |
| Jun 30, 2022 | -231,000.00 |
| Mar 31, 2022 | -7.98 Mn |
| Mar 31, 2022 | -7.98 Mn |
| Sep 30, 2021 | -996,000.00 |
| Sep 30, 2021 | -996,000.00 |
| Jun 30, 2021 | 798,000.00 |
| Jun 30, 2021 | 798,000.00 |
| Mar 31, 2021 | -5.06 Mn |
| Mar 31, 2021 | -5.06 Mn |
| Sep 30, 2018 | -93,000.00 |
| Sep 30, 2018 | -93,000.00 |